Strategies and Treatments for Respiratory Infections & Viral Emergencies

A multicenter, adaptive, randomised controlled trial platform to evaluate the safety and effectiveness of strategies and treatments for hospitalised patients with respiratory infections

What is this study about?

STRIVE (INSIGHT Protocol Number: 018/ACTIV) is a master protocol designed to evaluate the safety and effectiveness of unlicensed and licensed treatments and their sequential and combined use to optimise the health of patients admitted to hospital for acute care of a respiratory infection.

The protocol aims to improve standard of care by ensuring an agile research infrastructure, with the ability to rapidly assess interventions during epidemic transmission of one or more respiratory pathogens adversely affecting public health. Trials within this protocol can be adaptive, will be randomised, and will assess superiority as the primary objective.

STRIVE will enrol thousands of adults hospitalised with a respiratory virus. While the focus is initially on COVID-19, the master protocol is expected to expand to include other respiratory viruses including influenza. Any investigational agent(s) shown to be effective has the potential to become the new standard-of-care treatment, with far-reaching global benefits.

Type of study

Randomised trial

Contact details

Who is funding the study?

This study is funded by the National Institute of Allergy and Infectious Diseases, National Institutes of Health (USA).

When is it taking place?

STRIVE opened in 2022 and is expected to run until 2026.

Where is it taking place?

Approximately 190 sites in North America, South America, the UK and European Union, Australia, Africa and Asia.
Sites affiliated with the MRC CTU at UCL are located in the UK, Ireland, Greece, Uganda, Mozambique, and Zimbabwe.

Who is included?

Adults aged 18 years and older who are hospitalised with COVID-19.